FDA & Rare Disease Drugs: Why Policy and Politics Are Heating Up

Why It Matters

The guidance could dramatically shorten time‑to‑market for life‑saving therapies targeting ultra‑rare patients, while also reshaping biotech investment strategies and regulatory risk assessments.

Key Takeaways

• FDA draft guidance aims faster approvals for ultra‑rare therapies.
• Five criteria define “strong enough” science for single‑patient studies.
• Venet Prasad’s exit raises uncertainty over guidance’s longevity.
• Rare disease market projected to double, yet 90% lack treatments.
• Framework allows bundling multiple mutation‑specific therapies in one filing.

Summary

The episode focuses on the FDA’s new draft guidance designed to streamline approval pathways for ultra‑rare, often single‑patient, therapies. Host Jeff Buyers and guest Leslie Erlac discuss the policy shift against the backdrop of recent leadership turmoil, notably the departure of Venet Prasad, who oversaw vaccines, gene therapies and biologics.

Erlac outlines the market’s scale—about $245 billion globally and projected to more than double—while noting that roughly 90% of the 7,000 known rare diseases still lack FDA‑approved treatments. The guidance proposes five scientific criteria—identifying the genetic cause, direct targeting, natural history data, target engagement, and demonstrable clinical improvement—to substitute for traditional large‑scale trials. This represents a fundamental move from counting trials to evaluating the totality of evidence.

The conversation cites concrete examples: the controversial placebo‑surgery requirement for a Huntington’s disease gene therapy, the “baby KJ” case that inspired the framework, and a recent New England Journal of Medicine piece by Prasad and Marty McCarty arguing that trial quality, not quantity, safeguards patients. These anecdotes illustrate the tension between rapid access and rigorous validation.

If adopted, the guidance could accelerate development for small biotech firms, allowing them to bundle multiple mutation‑specific products under a single submission and reduce costly trial replication. However, the guidance remains draft, and leadership changes at the FDA may affect its durability, leaving investors and patient advocates watching closely for the final regulatory stance.

Original Description

Health Affairs' Jeff Byers welcomes Deputy Editor Leslie Erdelack back to the pod to break down recent turbulence at the FDA following the departure of Vinay Prasad, whose decisions around rare‑disease gene therapies courted controversy. They explore the fast‑growing rare disease therapeutics market, why traditional clinical trials often don’t work for ultra‑rare genetic conditions, and the new FDA draft guidance for rare disease drug development.

On March 24th, join us for our upcoming Insider exclusive event ( https://www.healthaffairs.org/do/10.1377/he20260218.815137/full/?utm_medium=podcast&utm_source=this+week&utm_campaign=insidermarketing&utm_content=eventspecific ) focusing on pharmacy benefit manager reform with Harvard Medical School's Benjamin Rome.

Become an Insider ( https://www.healthaffairs.org/subscribe/individual?utm_medium=podcast&utm_source=this+week&utm_campaign=insidermarketing&utm_content=eventspecific ) to get access to this event, trend reports, cheat sheets, and exclusive newsletters.

Related Articles:

* FDA vaccines chief who ran afoul of pharma to depart ( https://subscriber.politicopro.com/article/2026/03/fda-vaccines-chief-who-ran-afoul-of-pharma-to-depart-00817746?site=pro&prod=alert&prodname=alertmail&linktype=article&source=email ) (Politico)

* Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care ( https://www.prnewswire.com/news-releases/rare-disease-therapeutics-market-to-surpass-us-495-27-billion-by-2033-as-gene-therapy-rna-based-drugs-and-biologics-transform-patient-care-302577064.html?utm_source=chatgpt.com ) (PR Newswire)

* FDA NEWS RELEASE: FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases ( https://www.fda.gov/news-events/press-announcements/fda-launches-framework-accelerating-development-individualized-therapies-ultra-rare-diseases )

* FDA illuminates new approval pathway for bespoke gene editing therapies ( https://www.fiercebiotech.com/biotech/fda-illuminates-new-approval-pathway-bespoke-gene-therapies ) (Fierce Biotech)

* One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma ( https://www.nejm.org/doi/abs/10.1056/NEJMsb2517623 ) (The New England Journal of Medicine)

Health Affairs This Week

Episode 239

March 13, 2026

★ Episode details: https://share.transistor.fm/s/38d4e987

★ Additional episodes: http://www.healthaffairs.org